U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H25N3O7S
Molecular Weight 475.515
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERTAPENEM

SMILES

[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC4=CC=CC(=C4)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O

InChI

InChIKey=JUZNIMUFDBIJCM-ANEDZVCMSA-N
InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H25N3O7S
Molecular Weight 475.515
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/ppa/ertapenem.html | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22 | http://www.rxlist.com/invanz-drug.htm

Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem has been designed to be effective against Gram-negative and Gram-positive bacteria. The most common drug-related adverse experiences in patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), vaginitis in females (2.1%), phlebitis/thrombophlebitis (1.3%), and vomiting (1.1%). The coadministration with probenecid to extend the half-life of ertapenem is not recommended.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P0AD65
Gene ID: 945240.0
Gene Symbol: mrdA
Target Organism: Escherichia coli (strain K12)
Target ID: P0AD68
Gene ID: 944799.0
Gene Symbol: ftsI
Target Organism: Escherichia coli (strain K12)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

2001
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

2001
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

2001
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

2001
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
75.7 μg/mL
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
70.6 μg/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
155 μg/mL
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
663.1 ug/mL
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
506.4 μg × h/mL
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
541.8 μg × h/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6225 ug*h/mL
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.8 h
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4 h
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
19.3 h
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 g 1 times / day steady, intravenous
Highest studied dose
Dose: 3 g, 1 times / day
Route: intravenous
Route: steady
Dose: 3 g, 1 times / day
Sources:
healthy, 18-49 years
Health Status: healthy
Age Group: 18-49 years
Sex: M+F
Sources:
500 mg 1 times / day steady, intravenous (starting)
Dose: 500 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
vancomycin(1250 mg intravenous loading dose followed by 500 mg intravenously once the following day)
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Encephalopathy...
AEs leading to
discontinuation/dose reduction:
Encephalopathy (1 patient)
Sources:
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hallucinations, Delirium...
AEs leading to
discontinuation/dose reduction:
Hallucinations (1 patient)
Delirium (1 patient)
Sources:
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Disc. AE: Rash, Confusion...
AEs leading to
discontinuation/dose reduction:
Rash (1 patient)
Confusion (1 patient)
Seizure (1 patient)
Thrombocytopenia (1 patient)
Sources: Page: p. 184
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Other AEs: Diarrhea, Dizziness...
Other AEs:
Diarrhea (1 patient)
Dizziness (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Encephalopathy 1 patient
Disc. AE
500 mg 1 times / day steady, intravenous (starting)
Dose: 500 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
vancomycin(1250 mg intravenous loading dose followed by 500 mg intravenously once the following day)
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: M
Population Size: 1
Sources:
Delirium 1 patient
Disc. AE
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Hallucinations 1 patient
Disc. AE
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Confusion 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Rash 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Seizure 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Thrombocytopenia 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Diarrhea 1 patient
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Dizziness 1 patient
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >500 uM]
no [IC50 >500 uM]
no [IC50 >500 uM]
no
no
no
yes [IC50 56.2 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains.
2001 Aug
Gateways to Clinical Trials.
2002 Apr
In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials.
2002 Aug
Gateways to clinical trials.
2002 Jan-Feb
In vitro activity of ertapenem against bacterial isolates from cancer patients.
2002 Jul
Broad resistance due to plasmid-mediated AmpC beta-lactamases in clinical isolates of Escherichia coli.
2002 Jul 15
Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections.
2002 Jun
Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections.
2002 Jun
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
2002 Jun 1
Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone.
2002 Mar
Ertapenem (Invanz)--a new parenteral carbapenem.
2002 Mar 18
Use of surrogate antimicrobial agents to predict susceptibility to ertapenem.
2002 May
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
2002 Nov
Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections.
2002 Nov
Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection.
2002 Nov
Modified high-performance liquid chromatographic method for the determination of ertapenem in human urine: enhanced selectivity and automation.
2002 Nov 5
Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults.
2002 Sep
General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
2002 Sep 1
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
2002 Sep 1
Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
2002 Winter
Resistance in Enterobacteriaceae: results of a multicenter surveillance study, 1995-2000.
2003 Aug
New drugs 2003, part I.
2003 Feb
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
2003 Feb
Assay methodology for the quantitation of unbound ertapenem, a new carbapenem antibiotic, in human plasma.
2003 Jan 5
[New Beta-lactam agent in the treatment of intra-abdominal sepsis: double blind and randomized stage III study of ertapenem versus piperacillin/tazobactam].
2003 Jul-Sep
[Comparative in vitro activity of ertapenem against aerobic and anaerobic bacteria].
2003 Jun
Ertapenem therapy for community-acquired pneumonia in the elderly.
2003 Nov
New therapies for pneumococcal meningitis.
2004 Apr
Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam.
2004 Feb
Stability and compatibility of reconstituted ertapenem with commonly used i.v. infusion and coinfusion solutions.
2004 Jan 1
Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
2004 Jun
In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.
2004 Jun
Gateways to clinical trials.
2004 Mar
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
2004 May 1
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems.
2005 Mar
In vitro activity of ertapenem against bacteraemic pneumococci: report of a French multicentre study including 339 strains.
2005 Mar
Patents

Sample Use Guides

1 g given once a day. Intravenous infusion for up to 14 days or intramuscular injection for up to 7 days.
Route of Administration: Other
The MICs of ertapenem are MIC(50) = 0.032 μg/ml; MIC(90) = 0.064 μg/ml in vitro activity of ertapenem against N.gonorrhoeae isolates.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:59:28 GMT 2023
Edited
by admin
on Fri Dec 15 15:59:28 GMT 2023
Record UNII
G32F6EID2H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ERTAPENEM
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
(4R,5S,6S)-3-(((3S,5S)-5-((M-CARBOXYPHENYL)CARBAMOYL)-3-PYRROLIDINYL)THIO)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 3-((5-(((3-CARBOXYPHENYL)AMINO)CARBONYL)-3-PYRROLIDINYL)THIO)-6-(1-HYDROXYETHYL)-4-METHYL-7-OXO-, (4R-(3(3S*,5S*), 4.ALPHA.,5.BETA.,6.BETA.(R*)))-
Systematic Name English
ERTAPENEM [MI]
Common Name English
Ertapenem [WHO-DD]
Common Name English
ertapenem [INN]
Common Name English
ERTAPENEM [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011294
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
NDF-RT N0000011294
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
NDF-RT N0000011294
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
NDF-RT N0000011294
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
NDF-RT N0000011294
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
NDF-RT N0000011294
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
NDF-RT N0000175496
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
NDF-RT N0000011294
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
WHO-ATC J01DH03
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
NCI_THESAURUS C260
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
WHO-VATC QJ01DH03
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
NDF-RT N0000011294
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
NDF-RT N0000011294
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
LIVERTOX NBK548006
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
Code System Code Type Description
FDA UNII
G32F6EID2H
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
LACTMED
Ertapenem
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
DAILYMED
G32F6EID2H
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
MESH
C446479
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
RXCUI
325642
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY RxNorm
EVMPD
SUB25388
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
DRUG CENTRAL
1046
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
MERCK INDEX
m5001
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY Merck Index
DRUG BANK
DB00303
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
HSDB
8020
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
CAS
153832-46-3
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
PUBCHEM
150610
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
CHEBI
404903
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
NCI_THESAURUS
C61752
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
SMS_ID
100000089365
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
INN
8049
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
EPA CompTox
DTXSID50165456
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
ChEMBL
CHEMBL1359
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
WIKIPEDIA
ERTAPENEM
Created by admin on Fri Dec 15 15:59:28 GMT 2023 , Edited by admin on Fri Dec 15 15:59:28 GMT 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
ENZYME->SUBSTRATE
Low level activity could still lead to resistance to the antibiotic.
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
SALT/SOLVATE -> PARENT
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
LIGAND->BINDER
BINDING
TARGET ORGANISM->INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
MINOR
URINE
METABOLITE INACTIVE -> PARENT
MAJOR
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC